ClinicalTrials.gg
RecruitingNCT05920629ModerateUpdated Apr 28, 2026

Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction

An interventional study of Alcohol consumption in Myocardial Infarction, sponsored by Baris Gencer. Recruiting at 4 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Baris Gencer · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.

Planned enrollment
30th of 51
220 · median 334
Started
2023
with 2 others
No phase
24 of 69
6 open now
Primary completion
2026-04
later than 0 of 19 live
Registered
60th of 69
by date

Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 30th largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2023, is one of 24 with no phase, reaches primary completion later than 0 of the 19 other live ones, and was the 60th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Myocardial Infarction with a site in Switzerland, or all of them as a file.
02

Study summary

A total of 220 patients (110 per arm) who report moderate alcohol consumption between 1 and 28 standard units (1 standard unit = \~10 grams) per week in the 12 months prior to hospital admission will be planned for randomization, using a 1:1 ratio to pursue moderate alcohol consumption (1 standard unit per day for women and 2 standard units per day for men) or abstinence (except for one drink on predefined/agreed special occasions) for a total duration of 3 months. An echocardiography will be performed at baseline and 3 months to assess changes in systolic cardiac function (LVEF) for the primary endpoint. A core laboratory team blinded to assignment will perform data interpretation.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalization for acute ST-elevation MI (STEMI) or non ST-elevation MI (NSTEMI) within 365 days prior to screening
  • Men and women aged ≥18 years who are capable and willing to provide consent
  • ischemic changes, such as persistent or dynamic ST-segment deviation
  • Evidence of positive high-sensitive troponin
  • Confirmation of coronary heart disease aetiology by angiography
  • Capacity to complete study visits with strict adherence to the protocol assignment
  • Self-reported average alcohol consumption of between 1 and 28 standard units per week in the 12 months prior to the index hospitalization.

Exclusion criteria

Exclusion Criteria:

  • High alcohol consumption, defined as an average of >28 alcoholic standard units/week in the 12 months prior to the index hospitalization
  • Alcohol use disorder (AUDIT score >20 at screening)
  • History of alcohol or substance abuse
  • Naïve to alcohol consumption
  • Light alcohol consumption (\<1 standard units by week)
  • Prior severe heart failure ( III-IV)
  • Severe LV dysfunction at screening (\<30%)
  • History of gastric ulcer or gastro-intestinal bleeding
  • Serious chronic liver disease or liver test elevation (> 3 times upper limit normal range)
  • Personal history of any colon or liver cancer
  • Any active (less than 5 years or ongoing treatment)
  • Estimated 15 ml/min/1.73m² or end-stage renal disease
  • Any medication (investigator's discretion) making study participation impractical or precluding required follow-up
  • History of organ transplant
  • Participation in another trial testing intervention on similar CV outcomes (investigator's discretion)
  • Any medical, geographic, or social factor making study participation impractical or precluding required follow-up.
  • Pregnant, breastfeeding or planning to become pregnant within 12 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • No intervention
    Moderate alcohol consumption

    1 standard unit a day for 3 months

  • Other
    Abstinence

    No alcohol beverages for 3 months

    Behavioral: Alcohol consumption

Interventions

  • BehavioralAlcohol consumption

    After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 3 months. We will perform a first echocardiography at randomization and a second at 3 months' follow-up.

06

What researchers measure

Primary outcomes

  1. Cardiac function

    Measurement of change in left ventricular ejection fraction between baseline visit and 3-month visit

    Time frame: 3 months

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2026, 34 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 34 months is close to that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Jun 27, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05920629
Lead sponsor
Baris Gencer
Collaborators
University of Bern, Swiss National Science Foundation
Responsible party
Baris Gencer (Principal Investigator, University Hospital, Geneva) — Sponsor-investigator
First posted
Jun 27, 2023
Start date
Jun 1, 2023
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

Baris Gencer, MD
Contact
baris.gencer@chuv.ch
+41 79 556 59 60
Baris Gencer, MD
principal investigator · CHUV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion